<DOC>
	<DOCNO>NCT01337427</DOCNO>
	<brief_summary>This research sub-study complete part Multicenter , Randomized , Double-Blind , Parallel-Group , Placebo-Controlled Study Evaluate Efficacy Safety PEGylated Interferon Beta-1a ( BIIB017 ) Subjects Relapsing Multiple Sclerosis ( Protocol # : NA_00028117 ) . This substudy do understand efficacy BIIB017 measure nerve fiber thickness eye .</brief_summary>
	<brief_title>Using Optical Coherence Tomography ( OCT ) Evaluate Efficacy Safety PEGylated Interferon Beta-1a ( BIIB017 ) Patients With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . A participant ADVANCE study age 18 55 year old , inclusive , time informed consent As per ADVANCE main study History intraocular surgery , retinal disease , glaucoma , diabetes Refractive error Â±6.0 diopter Inability tolerate OCT procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>relapse</keyword>
	<keyword>MS</keyword>
	<keyword>injectable</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>SC</keyword>
	<keyword>PEGylated</keyword>
	<keyword>interferon</keyword>
	<keyword>PEG</keyword>
	<keyword>OCT</keyword>
	<keyword>Optical Coherence Tomography</keyword>
</DOC>